See more : Dana Incorporated (DAN) Income Statement Analysis – Financial Results
Complete financial analysis of Savara Inc. (SVRA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Savara Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Rubicon Technology, Inc. (RBCN) Income Statement Analysis – Financial Results
- Protara Therapeutics, Inc. (TARA) Income Statement Analysis – Financial Results
- Koito Manufacturing Co., Ltd. (KOTMY) Income Statement Analysis – Financial Results
- Guangdong Dongfang Precision Science & Technology Co., Ltd. (002611.SZ) Income Statement Analysis – Financial Results
- DongKook Pharmaceutical Co., Ltd. (086450.KQ) Income Statement Analysis – Financial Results
Savara Inc. (SVRA)
About Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 257.00K | 0.00 | 0.00 | 0.00 | 400.00K | 54.00 | 1.55K | 0.00 | 0.00 | 0.00 | 488.96K | 300.00K | 500.00K | 500.00K | 0.00 | 496.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 44.26M | 167.00K | 367.00K | 35.04K | 1.01M | 526.00K | 363.00K | 0.00 | 146.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -44.26M | -167.00K | -367.00K | 221.96K | -1.01M | -526.00K | -363.00K | 400.00K | -145.95K | 1.55K | 0.00 | 0.00 | 0.00 | 488.96K | 300.00K | 500.00K | 500.00K | 0.00 | 496.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 86.37% | 0.00% | 0.00% | 0.00% | 100.00% | -270,270.37% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 44.26M | 27.88M | 28.99M | 35.04M | 38.78M | 37.17M | 18.51M | 8.18M | 28.26M | 19.44M | 12.90M | 8.09M | 5.76M | 3.69M | 6.51M | 17.92M | 15.93M | 12.00M | 8.68M | 2.74M | 749.00K | 282.97K | 946.42K | 1.02M |
| General & Administrative | 15.67M | 10.93M | 12.35M | 14.26M | 13.08M | 10.65M | 11.08M | 2.82M | 10.96M | 9.49M | 8.52M | 7.52M | 7.60M | 5.32M | 5.00M | 9.72M | 8.68M | 7.24M | 4.90M | 4.02M | 1.59M | 1.39M | 2.04M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -410.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.67M | 10.93M | 12.35M | 14.26M | 13.08M | 10.65M | 11.08M | 2.82M | 10.96M | 9.49M | 8.52M | 7.52M | 7.19M | 5.32M | 5.00M | 9.72M | 8.68M | 7.24M | 4.90M | 4.02M | 1.59M | 1.39M | 2.04M | 793.97K |
| Other Expenses | -44.19M | -765.00K | -708.00K | -638.00K | 311.00K | 526.00K | 363.00K | -43.00K | 4.00K | 508.00K | -1.35K | -5.05K | 37.57K | 19.82K | 79.73K | 168.04K | 197.78K | 176.69K | 115.55K | 41.31K | 8.97K | 428.11K | 7.67M | 0.00 |
| Operating Expenses | 15.75M | 38.04M | 40.63M | 48.66M | 52.17M | 48.35M | 29.96M | 11.35M | 39.37M | 29.01M | 21.46M | 15.70M | 13.40M | 9.03M | 11.59M | 27.81M | 24.81M | 19.41M | 13.70M | 6.80M | 2.34M | 2.10M | 10.66M | 3.72M |
| Cost & Expenses | 60.01M | 38.04M | 40.63M | 48.66M | 52.17M | 48.35M | 29.96M | 11.35M | 39.37M | 29.01M | 21.46M | 15.70M | 13.40M | 9.03M | 11.59M | 27.81M | 24.81M | 19.41M | 13.70M | 6.80M | 2.34M | 2.10M | 10.66M | 3.72M |
| Interest Income | 4.44M | 88.00 | 2.28K | 1.48K | 0.00 | 0.00 | 0.00 | 122.00K | 130.00K | 69.00K | 60.27K | 73.56K | 76.59K | 92.87K | 7.16K | 549.96K | 2.17M | 1.16M | 496.06K | 103.04K | 9.27K | 1.27K | 31.69K | 40.92K |
| Interest Expense | 0.00 | 88.00K | 2.28M | 1.48M | 70.00K | 11.00K | 1.16M | 468.00K | 603.00K | 0.00 | 0.00 | 0.00 | 11.01K | 1.63K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.39K | 1.39K | 53.70K | 12.02K | 23.50K |
| Depreciation & Amortization | 175.00K | 167.00K | 367.00K | 693.00K | 1.01M | 526.00K | 363.00K | 346.00K | 146.00K | 85.00K | 39.52K | 90.05K | 38.00K | 19.82K | 79.73K | 168.04K | 197.78K | 176.69K | 115.55K | 41.31K | 8.97K | 428.11K | 7.67M | 1.91M |
| EBITDA | -59.13M | -37.90M | -40.37M | -47.44M | -77.09M | -69.50M | -31.91M | -10.48M | -39.09M | -28.62M | -21.44M | -15.47M | -13.22M | -8.43M | -11.21M | -27.14M | -24.11M | -29.16M | -13.09M | -6.66M | -2.32M | -1.72M | 2.72M | -1.81M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -18,565.76% | 0.00% | 0.00% | 0.00% | -2,650.50% | -72,642,592.59% | -1,850,904.39% | 0.00% | 0.00% | 0.00% | -1,741.95% | -3,719.81% | -5,318.37% | -4,822.65% | 0.00% | -303.95% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -60.01M | -38.84M | -41.48M | -49.30M | -79.03M | -70.05M | -29.96M | -10.95M | -39.37M | -29.28M | -21.54M | -15.63M | -13.40M | -8.54M | -11.29M | -27.31M | -24.31M | -29.84M | -13.20M | -6.80M | -2.34M | -2.10M | -10.66M | -3.72M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -19,182.88% | 0.00% | 0.00% | 0.00% | -2,737.00% | -72,912,962.96% | -1,891,408.27% | 0.00% | 0.00% | 0.00% | -1,746.51% | -3,761.90% | -5,461.97% | -4,862.21% | 0.00% | -2,661.58% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 5.31M | 689.00K | -1.54M | -315.00K | 852.00K | 18.00K | -3.48M | -332.00K | -469.00K | 577.00K | 58.92K | 68.51K | -273.93K | 88.78K | -39.37K | 662.34K | 2.17M | 504.69K | -11.58M | 103.04K | 11.49K | 45.79K | -5.70M | 0.00 |
| Income Before Tax | -54.70M | -38.15M | -43.01M | -49.62M | -78.17M | -70.03M | -33.43M | -11.28M | -39.84M | -28.70M | -21.48M | -15.56M | -13.26M | -8.45M | -11.33M | -26.65M | -22.14M | 29.33M | -24.78M | -2.33M | -2.33M | -2.05M | -16.36M | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -19,305.45% | 0.00% | 0.00% | 0.00% | -2,820.00% | -73,781,481.48% | -1,854,134.37% | 0.00% | 0.00% | 0.00% | -1,728.35% | -3,775.02% | -5,329.50% | -4,428.41% | 0.00% | -4,995.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 796.00K | 2.28M | 1.48M | 26.85M | -8.51M | -3.63M | -357.00K | 473.00K | -306.00K | -1.35K | -5.05K | -65.62K | -88.78K | 39.37K | 0.00 | 0.00 | 9.92M | 11.58M | 4.37M | -11.49K | 6.63K | 5.68M | -17.43K |
| Net Income | -54.70M | -38.95M | -45.30M | -51.10M | -105.03M | -61.52M | -29.80M | -10.92M | -39.84M | -28.70M | -21.48M | -15.56M | -13.26M | -8.45M | -11.33M | -26.65M | -22.14M | -29.33M | -24.78M | -6.70M | -2.33M | -2.11M | -16.34M | -3.70M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -19,882.10% | 0.00% | 0.00% | 0.00% | -2,730.75% | -73,781,481.48% | -1,854,134.37% | 0.00% | 0.00% | 0.00% | -1,728.35% | -3,775.02% | -5,329.50% | -4,428.41% | 0.00% | -4,995.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.33 | -0.25 | -0.34 | -0.86 | -2.62 | -1.85 | -1.70 | -3.27 | -17.19 | -16.41 | -19.63 | -22.86 | -32.94 | -44.88 | -169.85 | -516.69 | -430.96 | -693.77 | -724.89 | -231.21 | -120.54 | -235.41 | -1.96K | -769.94 |
| EPS Diluted | -0.33 | -0.25 | -0.34 | -0.86 | -2.62 | -1.85 | -1.70 | -3.27 | -17.19 | -16.41 | -19.63 | -22.86 | -32.94 | -44.88 | -169.85 | -516.69 | -430.96 | -693.77 | -724.89 | -231.21 | -120.54 | -235.41 | -1.96K | -769.94 |
| Weighted Avg Shares Out | 165.20M | 152.77M | 133.92M | 59.31M | 40.03M | 33.30M | 17.52M | 3.35M | 2.32M | 1.75M | 1.09M | 680.60K | 402.51K | 188.30K | 66.68K | 51.57K | 51.38K | 42.28K | 34.19K | 28.98K | 19.35K | 8.95K | 8.34K | 4.81K |
| Weighted Avg Shares Out (Dil) | 165.20M | 152.77M | 133.92M | 59.31M | 40.03M | 33.30M | 17.52M | 3.35M | 2.32M | 1.75M | 1.09M | 680.60K | 402.51K | 188.30K | 66.68K | 51.57K | 51.38K | 42.28K | 34.19K | 28.98K | 19.35K | 8.95K | 8.34K | 4.81K |
Savara's rare lung disease drug meets main goal in late-stage study
Savara on Wednesday said its experimental drug, molgradex, met the main goal of a late-stage trial for treating a rare lung disease characterized by a feeling of breathlessness.
Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced positive results from the pivotal, Phase 3 IMPALA-2 clinical trial. IMPALA-2 is a 48-week, randomized, double-blind, placebo-controlled trial assessing the...
Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it will host a conference call and webcast tomorrow, Wednesday, June 26, 2024, at 8:00am ET to discuss top...
3 Penny Stocks Poised for Major Upside Over the Next 5 Years
Though risky, there are certainly plenty of penny stocks to buy that have the potential to significantly boost portfolio returns. Of course, patience and a growth-friendly market are required for the kind of major upside most growth investors are looking...
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
Penny stocks are some of the most affordable investments on the market, valued at less than $5. They can hold a unique and intriguing position that can be highly profitable.
Savara: The Binary Bet On Phase 3 Data
Savara is a biotech company focusing on the treatment of autoimmune pulmonary alveolar proteinosis. The company's valuation will be heavily impacted by the results of its upcoming IMPALA-2 trial for its drug Molgramostim. The trial results are expected to be...
Savara to Present at the Jefferies Global Healthcare Conference
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024 at 7:00am...
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego,...
Savara Announces New Employment Inducement Grant
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On May 14, 2024, the Compensation Committee of Savara's Board of Directors granted...
Savara Reports First Quarter 2024 Financial Results and Provides Business Update
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2024 and provided a business update. “The IMPALA-2 trial remains on-track and...
Source: https://incomestatements.info
Category: Stock Reports